The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable attention, particularly regarding retatrutide and tirzepatide. While both medications target both https://rorydgcp357668.techionblog.com/39032050/retatrutide-vs-tirzepatide-a-comparative-analysis